Nektar Therapeutics Plans Upcoming Financial Results Announcement
Nektar Therapeutics (NASDAQ: NKTR) is gearing up to share its financial results for the third quarter of 2024. This important update will be made available on an upcoming Thursday afternoon, specifically after the closing of financial markets in the United States. The announcement is anticipated by investors and stakeholders, offering insights into the company's performance and strategic direction.
Details of the Financial Results Call
Howard Robin, who serves as the President and CEO of Nektar Therapeutics, will lead a conference call to discuss the company's financial outcomes. The call is scheduled to commence at 5:00 p.m. Eastern Time, which is 2:00 p.m. Pacific Time. During this session, Howard will provide detailed commentary on the results, shedding light on the company’s performance metrics and future aspirations.
Accessing the Conference Call
Investors interested in attending the conference call are encouraged to pre-register to receive necessary dial-in information, including a PIN to access the live discussion. This proactive approach ensures efficient participation and engagement during the call, enabling stakeholders to gain real-time insights into the company’s financial standing.
About Nektar Therapeutics
Nektar Therapeutics is a prominent clinical-stage biotechnology firm dedicated to developing innovative therapies aimed at rectifying immunological dysfunctions prevalent in autoimmune and chronic inflammatory disorders. At the forefront of its research is rezpegaldesleukin (REZPEG or NKTR-358), a pioneering regulatory T cell stimulator currently undergoing evaluation in two Phase 2b clinical trials targeting atopic dermatitis and alopecia areata.
Moreover, Nektar is actively working on a preclinical candidate, NKTR-0165, which represents a bivalent tumor necrosis factor receptor type II agonist antibody. In collaboration with various partners, the company is exploring NKTR-255, an IL-15 receptor agonist designed to enhance the immune system’s natural capabilities in combating cancer, across multiple ongoing clinical studies. The innovative company is headquartered in San Francisco.
Investor and Media Contacts
For investors seeking additional information, they can reach out to Vivian Wu at Nektar Therapeutics. Her contact number is (628) 895-0661, providing assistance regarding financial details or inquiries related to the company’s activities.
Media representatives can connect with Madelin Hawtin of LifeSci Communications at 603-714-2638 for information and updates. Nektar values open communication with both investors and media, striving to provide accurate and timely information.
Frequently Asked Questions
When will Nektar Therapeutics announce its Q3 2024 financial results?
Nektar Therapeutics will announce its financial results for Q3 2024 on a Thursday afternoon after U.S. financial markets close.
Who will lead the conference call regarding the financial results?
The conference call will be hosted by Howard Robin, the President and CEO of Nektar Therapeutics.
What should investors do to participate in the conference call?
Investors should pre-register to obtain the dial-in information and a PIN for accessing the live call.
What is the main focus of Nektar Therapeutics?
Nektar Therapeutics is focused on developing treatments to correct immunological dysfunctions in autoimmune and chronic inflammatory diseases.
What is Nektar's lead product candidate?
The lead product candidate of Nektar Therapeutics is rezpegaldesleukin (REZPEG or NKTR-358), which is currently undergoing clinical trials.
